Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions
Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions
复制标题
DOI：
10.1128/jvi.03485-14
复制
发表时间：
2015-04-01
影响因子：
5.4
通讯作者：
Wainberg, Mark A.
中科院分区：
文献类型：
--
作者：
Anstett, Kaitlin;Mesplede, Thibault;Wainberg, Mark A.
新型整合酶链转移抑制剂 (INSTI) 多替拉韦 (DTG) 与此类旧药显示出有限的交叉耐药性，并在有治疗经验的患者中选择 R263K 替代。我们使用DTG进行组织培养选择，使用对旧INSTI具有抗性的病毒以及感染性和抗性测定，结果表明E92Q或N155H取代的存在与R263K的出现相容，而G140S Q148R、E92Q N155H、G140S、Y143R和Q148R取代则不然。
The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections with DTG, using viruses resistant to older INSTIs and infectivity and resistance assays, and showed that the presence of the E92Q or N155H substitution was compatible with the emergence of R263K, whereas the G140S Q148R, E92Q N155H, G140S, Y143R, and Q148R substitutions were not.